SAINT LAURENT, Quebec, March 23, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2017 financial results after market close on March 29, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, March 29, 2018
Time: 4:30 p.m. EDT
Conference dial-in: (833) 211-3233
International dial-in: (647) 689-3955
Conference ID: 6786519
Webcast Registration: Click here
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.